This study shows that the skin-microbiome in patients with eczema/atopic dermatitis is characterized by overgrowth of S. aureus bacteria. More overgrowth was linked to more severe symptoms. On the other hand a different bacterial species, S. epidermidis, was associated with reduced eczema severity. The study supports eczema treatment through elimination of only S. aureus. While antibiotics do not distinguish between 'good' and 'bad’ bacteria, this approach is possible with Staphefekt, the active ingredient in Gladskin Eczema products.